Tamsulosin + Solifenacin
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Lower Urinary Tract Symptoms
Conditions
Lower Urinary Tract Symptoms, Overactive Bladder, Benign Prostatic Hyperplasia (BPH)
Trial Timeline
Sep 1, 2007 → Apr 1, 2011
NCT ID
NCT02715024About Tamsulosin + Solifenacin
Tamsulosin + Solifenacin is a approved stage product being developed by Astellas Pharma for Lower Urinary Tract Symptoms. The current trial status is completed. This product is registered under clinical trial identifier NCT02715024. Target conditions include Lower Urinary Tract Symptoms, Overactive Bladder, Benign Prostatic Hyperplasia (BPH).
What happened to similar drugs?
4 of 13 similar drugs in Lower Urinary Tract Symptoms were approved
Approved (4) Terminated (1) Active (8)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01457573 | Approved | Completed |
| NCT02715024 | Approved | Completed |
Competing Products
20 competing products in Lower Urinary Tract Symptoms